about
Early investigational drugs for hearing loss.Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrolAdenosine A1 Receptor Protects Against Cisplatin Ototoxicity by Suppressing the NOX3/STAT1 Inflammatory Pathway in the Cochlea.PTPN22 gene polymorphisms in autoimmune diseases with special reference to systemic lupus erythematosus disease susceptibility.Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity.Association of (GT)n repeats promoter polymorphism of heme oxygenase-1 gene with serum bilirubin levels in healthy Indian adults.The Endocannabinoid/Cannabinoid Receptor 2 System Protects Against Cisplatin-Induced Hearing LossCapsaicin Protects Against Cisplatin Ototoxicity by Changing the STAT3/STAT1 Ratio and Activating Cannabinoid (CB2) Receptors in the CochleaIncreased Type I and Decreased Type II Hair Cells after Deletion of Sox2 in the Developing Mouse Utricle
P50
Q33847686-36DEC443-61B9-478C-B567-8E8495D6B914Q36361936-A8E26678-6B1F-4789-BBFB-207271AFF38BQ36768399-E1DCEA4D-B2FD-47AA-BFE3-ADAADCCE1CD1Q37782524-E814AED5-A57F-4598-B5FE-DC8ED009890FQ38681165-2BBAC0B7-4733-4B3D-BD48-3D3594AC194AQ54394493-87B0F98F-F37B-4A2C-A3C9-44843CE55F49Q58728851-54FA020B-BAA5-4319-997A-CD3B6593510DQ64109797-D9F08FDA-040B-4C2D-AAE3-CE26EAB54878Q91070271-11818BC6-9A0B-4AE1-993C-A918A65451EC
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Vikrant Borse
@ast
Vikrant Borse
@en
Vikrant Borse
@es
Vikrant Borse
@nl
type
label
Vikrant Borse
@ast
Vikrant Borse
@en
Vikrant Borse
@es
Vikrant Borse
@nl
prefLabel
Vikrant Borse
@ast
Vikrant Borse
@en
Vikrant Borse
@es
Vikrant Borse
@nl
P106
P31
P496
0000-0002-5280-2879